Ipilimumab vs Lenvatinib Mesylate

## Ipilimumab vs Lenvatinib Mesylate: Overview

This comparison examines the pharmacological differences between **Ipilimumab** and **Lenvatinib Mesylate**.

## Mechanism of Action

**Ipilimumab**: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

## Pharmacokinetics

**Half-life**: Ipilimumab — 14.7 days; Lenvatinib Mesylate — N/A.

## Chemical Properties

**Type**: Ipilimumab — Antibody; Lenvatinib Mesylate — Small molecule.